US regulator clears once-daily pill for late-stage pancreatic cancer
The US Food and Drug Administration has approved a new oral medication for patients with advanced pancreatic cancer. Developed by Revolution Medicines, the drug was shown in a major trial to double survival rates for those with metastatic disease. It is now available at a list price of $39,800 per month, with patient assistance programs offered.
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “FDA approves new drug Rasonque to treat advanced pancreatic cancer.” Browse more stories.